Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Adaptimmune Therapeutics ( (ADAP) ).
On September 22, 2025, Adaptimmune Therapeutics received a notice from the Nasdaq Hearings Panel granting an exception period to comply with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share. The company must meet this requirement by December 1, 2025, or face delisting from the Nasdaq Capital Market.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
Adaptimmune Therapeutics’ stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. Technical analysis suggests some short-term strength, but long-term trends remain bearish. The negative P/E ratio underscores valuation concerns, further weighing down the overall score.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a biotechnology company focused on developing T-cell therapies for cancer treatment.
Average Trading Volume: 74,632,918
Technical Sentiment Signal: Sell
Current Market Cap: $35.91M
Find detailed analytics on ADAP stock on TipRanks’ Stock Analysis page.